We are pleased to announce our research papers have been published in scientific journals.

Yasuda K, Shimodan S, Maehara N, Hirota A, Iijima R, Nishijima A, Mori H, Toyama R, Ito A, Yoshikawa Y, Arai S, Miyazaki T. AIM/CD5L ameliorates autoimmune arthritis by promoting removal of inflammatory DAMPs at the lesions. J Autoimmun. 2023, 142, 103149.

Research Fellow Kai Kudo* was awarded the "Encouragement Award" by the Japan Society of Clinical Chemistry (JSCC) in 2023.
*At the time of application, he was affiliated with Tokai University School of Medicine.

We are delighted to introduce an English version to our institute's website.

We are pleased to announce our research papers have been published in scientific journals.

Okanoue T, Yamaguchi K, Shima T, Mitsumoto Y, Katayama T, Okuda K, Mizuno M, Seko Y, Moriguchi M, Itoh Y, Miyazaki T. Artificial intelligence/neural network system that accurately diagnoses hepatocellular carcinoma in nonalcoholic steatohepatitis.
Hepatol Res. 2023, Online ahead of print.

Nemoto H, Honjo M, Arai S, Miyazaki T, Aihara M. Apoptosis inhibitor of macrophages/CD5L enhances phagocytosis in the trabecular meshwork cells and regulates ocular hypertension.
J Cell Physiol. 2023, Online ahead of print.

We are pleased to announce that FELISSIMO's "Neko-bu" (Cat club) has initiated the second phase of their AIM Medical Research Support Charity Project.
We extend our heartfelt gratitude for this initiative and assure you that IAM is dedicated to further accelerating drug development efforts.

For more information, please visit:
Neko-bu Blog
Special Website for AIM Medical Research Support Charity Project

We are delighted to share that Cygames Inc. has once again extended their generous support to us, building upon their previous year's contribution. On this occasion, we wish to convey our deep and heartfelt gratitude to Cygames Inc. The entire team at the research institute is wholeheartedly dedicated to advancing our efforts, aiming to finalize the development of AIM-based medication that holds the potential to revolutionize the treatment of both feline and human illnesses. Our utmost priority is to expedite the delivery of this groundbreaking solution to you, fulfilling the expectations you have kindly placed in us. We genuinely value your enduring support for IAM.
Warm regards,

Toru Miyazaki Director and President, IAM

We are pleased to announce that our institute has been designated as a research institution under Article 2 of the Regulations for the Handling of Grants-in-Aid for Scientific Research by the Ministry of Education, Culture, Sports, Science and Technology (MEXT).

Moving forward, we will continue to advance our research activities based on the established "Operation and Management of Public Research Funds and Measures Against Research Misconduct" framework within the institute.

It has been five months since IAM was established in April of this year. During this time, we have received numerous warm messages of support and generous donations from many of you. We are truly grateful, especially to those who have made significant contributions. While we have been individually expressing our gratitude to those who provided their contact information, we would like to take this moment to extend our heartfelt thanks to all of you for your kindness and support. Thank you very much.
With your support, both in terms of warm messages and financial contributions, the development of medicines for cats and humans is progressing smoothly. We are committed to working diligently in our research to meet your expectations and bring AIM medicine to the world as soon as possible. We appreciate your ongoing encouragement.

August 24, 2022
Director and President of IAM, Toru Miyazaki

We would like to express our sincere gratitude for the tremendous donations we have received through the "Neko ga 30 sai made ikiru hi" NFT Charity Project organized by Jiji Press Publishing Co., Ltd.
This initiative was conceptualized by the manga artist Kenjiro Hata, who generously created wonderful illustrations for the project. We extend our heartfelt thanks to him for his contribution.
Furthermore, we would also like to extend our gratitude to those who involved for their participation in the charity by contributing NFT art.
Thank you for your support and generosity.

Director and President of IAM, Toru Miyazaki

We are pleased to announce that Felissimo's "Neko-bu" has initiated the AIM Medical Research Support Charity Project. We extend our heartfelt gratitude to Felissimo for this initiative and express our dedication to further accelerate drug development efforts through IAM.

For more information, you can visit:
Neko-bu's Blog
Special Site for AIM Medical Research Support Charity Project